Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

European Commission Approves CPX-351 for Two Types of AML

The European Commission (EC) has approved CPX-351 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid...

FDA Approves Ivosidenib for Previously Treated, IDH1-Mutated AML

The FDA approved ivosidenib, a small-molecule IDH1 inhibitor, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and an...
On location

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...

Somatic Mutations and Co-Mutations Predict AML Risk in Women

According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...

FDA Places Partial Clinical Hold on AML and MDS Trial

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on a phase I/II trial of OXi4503, a vascular disrupting agent...
On location

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...
On location

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...
On location

Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML

Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...

FDA Approves IDH Inhibitor for Patients with AML

The U.S. Food and Drug Administration (FDA) has approved ivosidenib as the first IDH1 inhibitor for patients with relapsed or refractory acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.